Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

DSpace Repository

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

Author: Hurvitz, S. A.; Quek, R. G. W.; Turner, N. C.; Telli, M. L.; Rugo, H. S.; Mailliez, A.; Ettl, J.; Grischke, E.; Mina, L. A.; Balmana, J.; Fasching, P. A.; Bhattacharyya, H.; Hannah, A. L.; Robson, M. E.; Wardley, A. M.
Tübinger Autor(en):
Grischke, Eva-Maria
Published in: European Journal of Cancer (2018), Bd. 104, S. 160-168
Verlagsangabe: Elsevier Sci Ltd
Language: English
Full text: http://dx.doi.org/10.1016/j.ejca.2018.09.003
ISSN: 1879-0852
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)